ArticleJournal of virology2008
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.
Article in Journal of virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 83 citations in OpenAlex.
- HIV-1 superinfection occurs less frequently than initial infection in a cohort of high-risk Kenyan women.PLoS pathogens · 2013Trial
- Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses.Molecular biology · 2021Article
- Article
- Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.Journal of virology · 2019Article
- Production and Immunogenicity of Soluble Plant-Produced HIV-1 Subtype C Envelope gp140 Immunogens.Frontiers in plant science · 2019Article
- Characterization of the Neutralizing Antibody Response in a Case of Genetically Linked HIV Superinfection.The Journal of infectious diseases · 2018Article
- Superinfection Drives HIV Neutralizing Antibody Responses from Several B Cell Lineages that Contribute to a Polyclonal Repertoire.Cell reports · 2018Article
- Immunological and virological characteristics of human immunodeficiency virus type 1 superinfection: implications in vaccine design.Frontiers of medicine · 2017Review
- Intrasubtype B HIV-1 Superinfection Correlates with Delayed Neutralizing Antibody Response.Journal of virology · 2017Article
- Comprehensive Characterization of Humoral Correlates of Human Immunodeficiency Virus 1 Superinfection Acquisition in High-risk Kenyan Women.EBioMedicine · 2017Article
- The HIV-1 transmission bottleneck.Retrovirology · 2017Article
- The role of family planning in achieving safe pregnancy for serodiscordant couples: commentary from the United States government's interagency task force on family planning and HIV service integration.Journal of the International AIDS Society · 2017Review
- Article
- Identification and specificity of broadly neutralizing antibodies against HIV.Immunological reviews · 2017Review
- Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Deciphering Multiplicity of HIV-1C Infection: Transmission of Closely Related Multiple Viral Lineages.PloS one · 2016Article
- HIV-1 Superinfection Resembles Primary Infection.The Journal of infectious diseases · 2015Article
- Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa.The Journal of infectious diseases · 2015Article
- Low antibody-dependent cellular cytotoxicity responses in Zambians prior to HIV-1 intrasubtype C superinfection.Virology · 2014Article
- A critical question for HIV vaccine development: which antibodies to induce?Science (New York, N.Y.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Superinfection by a second human immunodeficiency virus type 1 (HIV-1) strain indicates that gaps in protective immunity occur during natural infection. To define the role of HIV-1-specific neutralizing antibodies (NAbs) in this setting, we examined NAb responses in 6 women who became superinfected between approximately 1 to 5 years following initial infection compared to 18 women with similar risk factors who did not. Although superinfected individuals had less NAb breadth than matched controls at approximately 1 year postinfection, no significant differences in the breadth or potency of NAb responses were observed just prior to the second infection. In fact, four of the six subjects had relatively broad and potent NAb responses prior to infection by the second strain. To more specifically examine the specificity of the NAbs against the superinfecting virus, these variants were cloned from five of the six individuals. The superinfecting variants did not appear to be inherently neutralization resistant, as measured against a pool of plasma from unrelated HIV-infected individuals. Moreover, the superinfected individuals were able to mount autologous NAb responses to these variants following reinfection. In addition, most superinfected individuals had NAbs that could neutralize their second viral strains prior to their reinfection, suggesting that the level of NAbs elicited during natural infection was not sufficient to block infection. These data indicate that preventing infection by vaccination will likely require broader and more potent NAb responses than those found in HIV-1-infected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.